仟源医药：子公司收到药品注册证书及化学原料药上市申请批准通知书

Core Viewpoint - The approval of the drug Eivocase tablets by the National Medical Products Administration is a significant milestone for Qianyuan Pharmaceutical, enhancing its product portfolio and market competitiveness, although future sales remain uncertain [1] Company Summary - Qianyuan Pharmaceutical's subsidiary, Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., received the drug registration certificate for Eivocase tablets [1] - Another subsidiary, Jiangsu Jiayi Pharmaceutical Co., Ltd., obtained the approval notice for the listing application of Eivocase as a chemical raw material drug [1] - Eivocase tablets are indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis and are classified as a Category B product in the national medical insurance catalog [1] Industry Summary - The approval of Eivocase tablets is expected to enrich the company's product structure and enhance its competitiveness in the pharmaceutical market [1] - The future sales performance of Eivocase tablets is subject to uncertainty, reflecting potential challenges in market acceptance and competition [1]